The 5-HT 5A receptor is arguably the least understood 5-HT receptor. Despite widespread expression in human and rodent brains it lacks specific ligands. Our previous results suggest that 5-HT 5A receptor antagonists may be effective against cognitive impairment in schizophrenia. In this study, using behavioral, immunohistochemical, electrophysiological and microdialysis techniques, we examined the mechanism by which ASP5736, a novel and selective 5-HT 5A receptor antagonist, exerts a positive effect in animal models of cognitive impairment. We first confirmed the effect of ASP5736 on cognitive deficits in rats treated subchronically with phencyclidine hydrochloride (PCP) using an attentional set shifting task. Subsequently, we identified 5-HT 5A receptors in dopaminergic (DAergic) neurons and parvalbumin (PV)-positive interneurons in the ventral tegmental area (VTA) and in PV-positive interneurons in the medial prefrontal cortex (mPFC). Burst firing of the DAergic cells in the parabrachial pigmental nucleus (PBP) in the VTA, which predominantly project to the mPFC, was significantly enhanced by treatment with ASP5736. In contrast, ASP5736 exerted no significant effect on either the firing rate or burst firing in the DA cells in the paranigral nucleus (PN), that project to the nucleus accumbens (N. Acc.). ASP5736 increased the release of DA and gamma-aminobutyric acid (GABA) in the mPFC of subchronically PCP-treated rats. These results support our hypothesis that ASP5736 might block the inhibitory 5-HT 5A receptors on DAergic neurons in the VTA that project to the mPFC, and interneurons in the mPFC, and thereby improve cognitive impairment by preferentially enhancing DAergic and GABAergic neurons in the mPFC.
Functional mechanism of ASP5736, a selective serotonin 5-HT 5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia Schizophrenia is a chronic, severe and disabling psychiatric disorder displaying both positive and negative as well as affective symptoms and profound cognitive deficits, including impaired working memory, attention and executive functioning (Elliott et al., 1995; Pantelis et al., 1999; Badcock et al., 2002) . Executive functioning is commonly assessed using the Wisconsin Card Sort Test (WCST) or the computerized intradimensional-extradimensional (ID-ED) shift test. The ID-ED shift test has been adapted for in nonhuman primates, where selective ED shift deficits similar to those observed in firstepisode schizophrenia patients can be induced by dorsolateral prefrontal cortex (PFC) lesions (Dias et al., 1996) . Subsequently, also the attentional set-shifting task was found applicable to rats (Birrell and Brown, 2000) , and impairment of the ability to switch attentional set by reduction of DA levels in the PFC was demonstrated (Crofts et al., 2001) . Using this test, modafinil, but not olanzapine, was reported to reverse cognitive deficits in rodents induced by subchronic phencyclidine hydrochloride (PCP) treatment (Pedersen et al., 2009; Rodefer et al., 2008) . Moreover, some studies (Madras et al., 2006; Hilaire et al., 2001; Dawson et al., 2012) reported that the ability of modafinil to improve cognitive flexibility in PCP-treated animals may be linked to its ability to increase DA levels in the PFC.
The 5-HT 5A receptor was cloned in 1994 (Rees et al.) , but few reports have described the function of the receptor due to a lack of specific ligands. Findings from 5-HT 5A receptor mRNA localization (Rees et al., 1994; Pasqualetti et al., 1998) and immunolabeling studies (Oliver and Kinsey, 2000) have revealed a widespread expression of this receptor in the central nervous system, including the cerebral cortex, hippocampus, the nucleus accumbens (N. Acc.), amygdala and hypothalamus. The increased exploratory behavior in novel environments displayed by 5-HT 5A receptor knockout mice compared to wild-type mice (Grailhe et al., 1999) , together with the receptor's widespread expression, has indicated that it may be involved in mood, affective disorders, and cognitive function. Gene association studies also suggest that the 5-HT 5A receptor may play a role in both schizophrenia and mood disorders (Thomas, 2006; JongenRelo et al., 2006; Rueter et al., 2006) .
We recently identified ASP5736, a novel selective antagonist of the 5-HT 5A receptor, and reported the in vitro and in vivo characterization of this compound (Yamazaki et al., 2014 (Yamazaki et al., , 2015 . Treatment with ASP5736 ameliorated cognitive impairment in animal models of schizophrenia and dementia. The compound bound to 5-HT 5A receptors at approximately 15-50% occupancy levels in behaviorally effective doses.
However, the mechanism of action of ASP5736 and its efficacy in various other animal models has not yet been clarified. Dopaminergic (DAergic) neurons in the ventral tegmental area (VTA) project to the N. Acc and to the PFC (Erhardt et al., 2002; Svensson et al., 1995; Svensson, 2000) . Whereas the neurons in the paranigral nucleus (PN) subdivision of the VTA largely project to the N. Acc, the neurons in the parabrachial pigmental nucleus (PBP), another subdivision of the VTA, predominantly project to the PFC (for review see Svensson, 2000) . Considering that ASP5736 improves cognitive impairment in animal models of schizophrenia without exacerbating positive symptom-like behavior (Yamazaki et al., 2014) , it would be of interest to evaluate the potential selectivity of ASP5736 for each DAergic pathway.
In this study, we examined the mechanism of action of ASP5736 with behavioral, immunohistochemical, electrophysiological and microdialysis techniques using rats. We first confirmed the effect of the compound on cognitive deficits using an attentional set-shifting task. We then examined the co-expression of 5-HT 5A receptors in DAergic neurons and parvalbumin (PV)-positive interneurons. Subsequently we evaluated the effect of the compound on the firing rate and burst firing of DA cells in the PBP and PN in the VTA. Finally, we evaluated the effect of ASP5736 on extracellular DA and gamma-aminobutyric acid (GABA) in the mPFC.
Experimental procedures
ASP5736 and PCP were synthesized at Astellas Pharma Inc. (Tsukuba, Japan). ASP5736 was suspended in 0.5% (w/v) methylcellulose and PCP was dissolved in saline. All compounds were administered at 1 mL/kg in rats. For in vivo electrophysiological experiments, ASP5736 was dissolved in a mixture of 10% polyoxyethylene castor oil (cremophor EL, Sigma) and 90% saline.
Animals for immunohistochemistry, attentional set shifting task (ASST), and microdialysis
Male Long Evans rats (Japan SLC, Inc.) were housed in groups of three in temperature-and humidity-controlled rooms (23 7 2 1C and 55 7 10%) under a 12-h light/dark cycle. Food and water were available ad libitum in the home cages except for ASST subjects, whose food was restricted prior to the test to enhance their performance on the food-motivated task. All animal experimental procedures were approved by the Institutional Animal Care and Use Committee of Astellas Pharma Inc. (Tsukuba Research Center is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International).
Animals for electrophysiological studies
Adult male Sprague-Dawley rats ( $300 g; Charles River Laboratories) were housed under standard laboratory conditions at a temperature of 21.0 7 0.4 1C and relative humidity of 55-65%, and maintained on a 12-h light/dark cycle. Food and water were available ad libitum. All experiments were approved by, and conducted in accordance with, the local Animal Ethics Committee and the Karolinska Institutet, Sweden.
ASST
Rats were administered intraperitoneal (i.p.) 2 mg/kg PCP or saline twice daily for 7 days within 9 days (excluding the weekend), followed by a 7-or 8-day washout period. The ASST was carried out in accordance with the methods of others (Birrell and Brown, 2000; Rodefer et al., 2005) , with some modifications. The test box (40 Â 60 Â 30 cm) was made of gray polyvinyl chloride with a slide-up door separating the start area from the choice area. The choice area (40 Â 40 Â 30 cm) was further divided by a low wall (25 Â 30 cm), and the digging bowls (7.6 cm in diameter and 4.1 cm in depth, terracotta) were placed on either side of the divider in the choice area. On the last day of the washout period, rats were allowed to freely explore the choice area without digging bowls for four minutes to habituate them to the test box. Rats were then returned to the start area and allowed once more to access the choice area, in which two digging bowls had been placed, to train them to dig for a food reward. Each bowl was filled with ALPHAdris (Shepherd Specialty Papers, Inc.) and contained two halves of a piece of cereal (Honey Nut Cheerios; General Mills), one in view on top of the paper and the second buried at the bottom of the bowl. When the rats had consumed all four cereal pieces or 20 minutes had lapsed, they were returned to their home cages. Trained rats, which had been able to eat at least three cereal pieces within the 20-min period, were moved on to the next phase of the experiment. Trained rats were presented the simple discrimination 1 (SD1) task as follows: the two digging bowls in the choice area were filled with either wooden or plastic beads. Lemon oil was applied to the rims of the bowls with wood beads and nutmeg oil was applied to the rims of the bowls with plastic beads. Only the bowl with plastic beads contained the food reward. The trial was started by opening the slide door, allowing the rats to return to the start area when they chose the food reward or started to dig in the incorrect bowl. The trial continued until rats met the criterion of five consecutive correct choices. On the next testing day, a series of six discrimination tasks (Table 1) were performed. Rats that had made the five correct choices were allowed to progress to the next discrimination task. Once the compound discrimination (CD) was passed, rats were returned to their home cages. While rats were resting in their home cages, ASP5736 or vehicle was administered (this corresponds to about 1 hour before the ED discrimination task.). The number of trials required to meet the criteria during each discrimination task was recorded. Rats expressing no interest in digging in the bowl or a food reward during any discrimination task were excluded.
Immunohistochemistry
Rats were anesthetized with isoflurane (Mylan) and perfused with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde in PBS (Wako Pure Chemical Industries). The brains were collected, immersed in 4% paraformaldehyde in PBS, and replaced to 10% and subsequently 30% sucrose in PBS. Brains were stored in an optimal cutting temperature compound (Sakura Finetek) at À80 1C.
Brains were cut into 20 μm coronal sections using a cryostat CM3050S (Leica Biosystems) onto glass slides. Brain slices were stored at À 80 1C. Fisher Scientific] in incubation buffer) for 1.5 h at room temperature. Following 5 min incubation with 5 μg/mL Hoechst 33342 fluorescent stain (Thermo Fisher Scientific) in PBS, sections were washed and coverslipped using FluorSave mounting medium (EMD Millipore). Sections were observed by confocal laser scanning microscopy LSM710 (Carl Zeiss). This polyclonal anti-5-HT 5A receptor antibody appears to be specific as not all cells are stained, but it has not been validated on KO tissue (by ourselves or in any other published study).
In vivo electrophysiological experiments
Rats were anesthetized with chloral hydrate (400 mg/kg i.p supplemental injections 150 mg/kg/h) and mounted in a stereotaxic frame. Body temperature was maintained at 37 1C. Recording microelectrodes were pulled in a vertical puller (Narishige) from borosilicate glass capillaries (Harvard Apparatus Ltd) with outer and inner diameters of 1.50 and 1.17 mm, respectively, and filled with Two digging bowls were placed in the test box (40 Â 60 Â 30 cm). The digging bowls were filled with different medium (e.g. corn chips/wood chips) and applied different aroma oil (e.g. ginger/mint) on the rim of the bowl, only one of them had the food reward. In each discrimination task, the medium-odor pairs of digging bowls were randomly changed trial-by-trial. The correct exemplar is shown in italic.
2% Pontamine Sky Blue in 2 M NaCl. The tips of the electrodes were broken to yield an impedance of 2-4 MΩ at 135 Hz. A hole was drilled above the VTA (3.2 mm anterior to the interaural line and 0.7 mm lateral to the midline (Paxinos and Watson 2007) ). The recording microelectrode was lowered into the brain by means of a hydraulic microdrive (David Kopf). Presumed dopamine neurons were found 7.5-9.0 mm below the brain surface and were recognized by their characteristic triphasic action potential waveform of more than 2.0 ms duration, basal firing rates of 1-10 Hz, and frequent burst firing (Wang, 1981) . Apomorphine inhibits DAergic cells firing (Grace and Bunney, 1983 ) and when possible, apomorphine was administered at the end of the experiment.
Extracellular electrical activity was amplified, filtered (band pass, 0.3-3 kHz), discriminated, and monitored using an oscilloscope (TDS 310, Tektronix) and an audio monitor (Grass, AM8B/C). Discriminated spikes were fed via a CED 1401 interface (Cambridge Electronic Design, Ltd.) to a computer running CED Spike 2 software. The mean firing rate was calculated as spikes per second (Hz) over periods of 300-500 spikes, depending on the firing rate. The onset of a burst was defined as an interspike time interval (ISI) of o 80 ms and burst termination as the next ISI exceeding 160 ms (Grace and Bunney, 1984) . Burst firing was expressed as the percentage of spikes fired in bursts.
Only one cell was studied in each animal. Cumulative doses of ASP5736 were intravenously administered and the time between injections was approximately 2-5 min depending on the firing rate. After experiment, the position of the electrode was marked by iontophoresis of Pontamine Sky Blue (5 μA for 5 min). The brains were removed and preserved in 25% sucrose and 4% formaldehyde. The brain was cut into 50 μm slices, stained with neutral red, and examined microscopically for verification of the recording site.
Microdialysis
Rats were administered 2 mg/kg PCP i.p. twice daily for 7 days within 9 days (excluding a weekend). On the 2nd or 3rd day after the completion of PCP treatment, rats were anesthetized with sodium pentobarbital and were stereotactically implanted with a microdialysis guide cannula with a dummy probe into the mPFC (AP +3.1 mm, ML À 0.8 mm, DV À2.0 mm from bregma). The cannula was fixed onto the skull and anchored with dental cement. Rats were allowed to recover from surgery for at least 4 days. On the day of the microdialysis study, the dummy probes were replaced with dialysis probes (A-I-4-03, 3 mm, Eicom Corp). The dialysis probes were perfused at a rate of 2.0 μL/min with Ringer's solution (147 mmol/L Na + , 4 mmol/L K + , 2.3 mmol/L Ca 2 + , 155.6 mmol/L Cl À ) 2.0 μL/min. Dialysate was collected every 20 min into sample tubes containing 10 μL of 0.1 mol/L phosphate buffer with 0.1 mmol/L EDTA-2Na. Following collection of baseline dialysates, ASP5736 or vehicle was orally administered. Twenty minutes after administration, a plastic object (LEGO s ) was presented for 20 min as a cognition-related stimulus. After all dialysates were obtained, the insertion positions of the dialysis probes were checked, and data from rats whose probes had moved were not used.
2.6.1. Analyses of DA. DA levels in the dialysates were measured using a HPLC-ECD system (EP-700, ECD-700, ATC-700, Eicom Corp.) on the day of microdialysis experiment. The chromatographic separations were done using an EICOMPAK CAX column in combination with a mobile phase (0.1 mol/L ammonium acetate buffer (pH 6.0) containing 30% methanol, 50 mg/L EDTA-2Na, and 0.05 mol/L sodium sulfate), the flow rate with 250 μL/min at 35 1C and the ECD at +450 mV against a silver/silver-chloride reference electrode.
Analyses of GABA.
The analyses were done with HPLC system (Shimadzu Corp.) equipped with mass spectrometry (QTRAP 5500 AB Sciex). A ZIC-HILIC column (Merck KGaA) was used for chromatographic separation with isocratic flow (33% water and 67% acetonitrile containing 0.05% formic acid) at a flow rate of 300 μL/min and the column temperature was 40 1C. ESI ( +) was used for the ionization mode of the mass spectrometry.
Statistical analysis
All values are expressed as mean 7 standard error of the mean (SEM).
ASST
A repeated-measures ANOVA with two factors, one within-subjects (discrimination: SD2, CD, ID, IDR, ED, EDR), and one betweensubjects (drug treatment) was performed. About the comparison between Saline-and PCP-veh, t-test followed 2-way ANOVA (discrimination Â treatment) was used. In drug effective analyses, Dunnett's multiple comparison test corrected post hoc comparisons were used on the endpoint measure, namely the number of trials required to achieve five consecutive correct responses. For all tests, p o 0.05 was considered significant.
In vivo electrophysiologic experiments
The effect of control (vehicle) or drug on firing rate was calculated as percent change from the baseline value. Data were statistically analyzed using the t-test for dependent samples. The effect of control or drug on burst firing was calculated as the difference from the baseline value. Since burst firing is non-normally distributed, the non-parametric Wilcoxon matched-pairs signed-rank test was used.
Microdialysis experiments
When the coefficient of variation of baseline values (mean value of the last three samples before vehicle or ASP5736 administration) was 4 20% (GABA) or 4 20% (DA), the data were excluded. All the data from the microdialysis study are expressed as percentages of the baseline value. And we calculated AUC (Area under the curve) from 0 min to 120 min of DA and GABA level after vehicle or ASP5736 0.01 mg/kg treatment. Student's t-test was used for statistical comparison of vehicle vs. ASP5736 0.01 mg/kg. In each analysis, it was judged that p o 0.05 was significant. Figure 1 shows the effect of ASP5736 on ASST in subchronically PCP-treated rats. ASP5736 or vehicle was administered about 1 hour before the ED discrimination task. In the case of saline-or PCP-veh administration, there were a significant main effect of discrimination (F(5, 60) = 8.772, po0.01), a main effect of PCP treatment (F(1, 12) = 21.06, p o 0.01) and a significant discrimination and PCP pretreatment interaction (F(5, 60) = 8.772, p o 0.01). Post hoc t-test analyses revealed that scPCP-treated rats showed significantly increased number of trials to reach criteria in ED shift (p o 0.01). However, PCP treatment did not affect the number of trials to reach criteria in the other discrimination tasks (all ps 4 0.05), suggesting that the deficits were selectively induced in ED shift. On the other hand, examination of the behavioral effects of ASP5736 (0, 0.001, 0.003 and 0.01 mg/kg, po) revealed a significant effect of discrimination (F(5, 110) = 26.02, p o 0.01) and furthermore, significant effect of ASP5736 dosage (F(3, 22) = 4.189, p o 0.05) and ASP5736 Â discrimination interaction (F(15, 110) = 2.154, p o 0.05). Post hoc Dunnett's multiple comparison test analyses showed all dosages of ASP5736 significantly ameliorated the deficits in ED shift compared to vehicle treatment (all ps o 0.01). In all the other discrimination tasks, the number of trials to reach the criteria were not affected by ASP5736.
Results

ASST
Immunohistochemistry
Immunoreactivity of 5-HT 5A receptors was identified in the VTA region ( Figure 2A1 ). Tyrosine hydroxylase (TH) immunoreactivity was also identified in the VTA ( Figure 2A2 ). 5-HT 5A receptors were found on a part of TH-positive DAergic neurons in the VTA ( Figure 2A4 ). PV immunoreactivity was observed in the VTA (Figure 2B2 ), but very few (1-2 per section) PV-positive neurons were found. 5-HT 5A receptors were found on PV-positive interneurons in the VTA ( Figure 2B4 ). Immunoreactivity of 5-HT 5A receptors was also identified in the mPFC ( Figure 2C1 ). There were PV-positive neurons in the mPFC ( Figure 2C2 ). Double staining with 5-HT 5A receptors was found on PV-positive neurons ( Figure 2C4 ) in the mPFC.
In vivo electrophysiological experiments
The average firing rate across all cells (VTA Total) recorded was 4.28 7 0.31 Hz (mean 7 SEM, n = 28, Figure 3A) . Burst firing is a non-normally distributed parameter and the overall median burst firing was 13.18% (range, 0.5-93.1%). Cumulative doses of ASP5736 (0.01-0.08 mg/kg i.v.) were administered. Compared to control, 0.02 and 0.04 mg/kg significantly (p = 0.0285, 0.0220, respectively) increased firing rate. Furthermore, the effect of ASP5736 on burst firing also seemed biphasic with significant increases after 0.02 and 0.04 mg/kg (p = 0.0040 and p = 0.0230, respectively, Figure 3B ), but not after 0.08 mg/kg.
The dopaminergic cells were further subdivided according to their location within the VTA, i.e. the PBP and the paranigral nucleus (PN), respectively.
For the cells in the PBP (Figure 3C, D) , the average firing rate was 4.60 7 0.35 Hz (n = 18) and the median burst firing was 8.87%. Compared to the control, there was no significant effect of ASP5736 on firing rate. However, the burst firing was significantly increased by this compound after 0.02 and 0.04 mg/kg (p = 0.0029, 0.0108, respectively), but not after 0.08 mg/kg. Figure 1 Effect of ASP5736 on ED shift deficit in subchronically PCP-treated rats. The ASST was performed in subchronically (twice daily for 7 days) PCP-treated rats. ASP5736 or vehicle was administered about 1 hour before the ED discrimination task. Rats treated with scPCP +Veh were significantly impaired in ED shift compared to rats treated with scSaline +Veh. ASP5736 reversed the scPCP-induced ED impaiement at any doses examined (separate groups of rats were used for each ASP5736 dose). Each score shows the mean 7 SEM (n = 6 for 0.001 mg/kg and 0.01 mg /kg; n = 7 for the other groups). ##: p o 0.01 vs. subchronic saline group (t-test followed 2-way ANOVA). **: p o 0.01 vs. subchronic PCP +vehicle group (Dunnett's multiple comparison test followed 2-way ANOVA). ASST, Attentional set shifting task; PCP, phencyclidine hydrochloride; scSaline, subchronic saline group; scPCP, subchronic PCP group; Veh, vehicle; SD2, Simple discrimination 2; CD, Compound discrimination; ID, Intradimensional; IDR, ID-Reversal; ED, Extradimensional; EDR, ED-Reversal. Figure 2 Neurons in VTA or mPFC coexpress TH or PV and 5-HT 5A receptors. A: Representative section through the VTA stained with an antibody to 5-HT 5A receptors (1, green, arrow), TH (2, red, arrow) and Hoechst fluorescent (3, blue), (4, merged image, arrow). B: An example of a section of the VTA stained with an antibody to 5-HT 5A receptors (1, green, arrow), PV (2, red, arrow) and Hoechst fluorescent (3, blue), (4) merged image, arrow. C: An example of a section of the mPFC stained with an antibody to 5-HT 5A receptors (1, green, arrow), PV (2, red, arrow) and Hoechst fluorescent (3, blue), (4) merged image, arrow. mPFC, medial prefrontal cortex; PV, parvalbumin; TH, tyrosine hydroxylase; VTA, ventral tegmental area. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.). (Figure 3E, F) , the average firing rate was 3.94 7 0.56 Hz (n = 9) and the median burst firing was 16.23%. No significant effects were revealed on either firing rate or burst firing.
VTA PV
For the cells in the PN
Microdialysis
DA and GABA levels of mPFC in subchronically PCP-treated rats were measured ( Figure 4A and B) . Total DA release during 120 min after administration of 0.01 mg/kg of ASP5736 was significantly (p = 0.0371, t = 2.287) increased than that after administration of vehicle ( Figure 4C) . Furthermore, 0.01 mg/kg of ASP5736 also significantly (p = 0.0487, t = 2.175) increased total GABA release from 0 min to 120 min after administration compared with vehicle. (Figure 4D ).
Discussion
DAergic neurons in the VTA largely project in two directions, one toward the PFC and the second toward the N. Acc. DAergic neurons in the PBP, a subdivision of the VTA, largely project to the PFC while neurons in the PN, another subdivision of the VTA, project largely to the N. Acc (see Svensson et al., 1995) . The major finding of our study is that in the electrophysiological experiments, ASP5736 preferentially stimulated the burst firing mode in VTA dopamine neurons, especially those located in the PBP but had no effect in the PN, indicating enhanced dopamine release and DA-D 1 receptor activation in PBP target areas (see Chergui et al., 1996) . In this study, 5-HT 5A receptors were identified on DAergic neurons (TH-positive) and GABAergic neurons (PV-positive) in the VTA. These results suggest that ASP5736, in similarity with drugs with a prominent 5-HT 2A receptor blocking action (Svensson et al., 1995) selectively enhances DAergic neurons projecting from VTA to the PFC, which is related to cognitive impairment and negative symptoms in schizophrenia, without activating DAergic VTA neurons that projects to associative striatum which is related to psychotic symptoms (c.f. Slifstein et al., 2015) .
ASP5736 can partially ameliorate methamphetamine hydrochloride (MAP)-and (+)-5-methyl-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-5, 10-imine maleate (MK-801)-induced hyperactivity without binding to D 2 receptors (Yamazaki et al., 2014) . MK-801-and MAP-induced hyperactivity is reported to be associated with an increase in DA levels in N. Acc dialysates (Mathé et al., 1998) . In this study, ASP5736 exerted no significant effect on either the firing rate or burst firing in the DA cells in the PN, that project to the N. Acc. ASP5736 might block the inhibitory 5-HT 5A receptors on the GABAergic neurons in the VTA and suppress the DAergic neurons from the VTA to the N. Acc ( Figure 5 ). In contrast, this compound might also enhance DA neuronal activity in the VTA projecting to the N. Acc. These are opposite effects, which may be related to a higher density of GABA A receptors within the PN compared to the PBP (Churchill et al., 1992) . Thus, ASP5736 might partially inhibit DAergic neurons from the VTA to the N. Acc indirectly via GABAergic neurons (c.f. Erhardt et al., 2002) . The mechanisms of ASP5736 to ameliorate MAP-and MK-801-induced hyperactivity still remain to be clarified. Furthermore, our data indicate a biphasic dose-response curve for the effects of ASP5736 on both burst firing and firing rate of the VTA dopamine neurons taken as a group. Thus, whereas low doses (0.02-0.04 mg/kg i.v.) generated a slight but significant increase in both functional parameters, the highest dose tested (0.08 mg/kg i.v.) did not. These data suggest that the optimal effect of ASP5736 on cognitive functioning may reside within a relatively low dose range. This conclusion seems justified given that, for cells in PBP, ASP5736 generated both a significant and selective enhancement of the burst firing, but not of the firing rate, at 0.02 and 0.04 mg/kg i.v., but not at 0.08 mg/kg i.v. Interestingly, the burst firing dose response effects appeared biphasic, in analogy with the cognitive enhancing effects of ASP5736 on deficit models in rodents (Yamazaki et al., 2014) . The doses that alter firing rate and bursting are higher than the doses used in the behavioral and microdialysis studies. The doses used in the behavioral and microdialysis experiments involved awake rats that had been subchronically pretreated (twice daily for 7 days) with the N-methyl-D-aspartic acid (NMDA) receptor antagonist PCP (see Experimental procedures. Section 2.3 ASST and 2.6 Microdialysis, respectively), whereas our electrophysiological experiments were performed on anesthetized rats without any pretreatment with PCP (Experimental procedures, Section 2.5, c.f above). For these reasons alone it would, if anything, be surprising to find similar or identical dose-response relationships under these different conditions. Moreover, a recent study (Nikiforuk et al., 2016) . using another 5-HT 5A receptor antagonist, found that rats treated with ketamine, which like PCP is a NMDA receptor antagonist, required a lower effective dose of the 5-HT 5A antagonist to reverse the ketamine-induced ASST deficits, than their vehicle-treated control animals in principle analogous to our present results.
PCP is a non-competitive NMDA receptor antagonist that can induce a psychotic state with strong similarities to schizophrenia (c.f. Domingo and Luby, 2012) . PCP or ketamine given acutely to healthy human subjects may induce hyperactivity, paranoia, hallucinations, formal thought disorder, and cognitive impairment (Javitt and Zukin, 1991; Jentsch et al., 1997) . Subchronic PCP treatment in animals has been shown to produce more persistent effects on stereotypy and locomotor activity (Castellani and Adams, 1981; Sturgeon et al., 1982) , and to produce more enduring cognitive deficits of particular relevance to schizophrenia (Abdul-Monim et al., 2006 Hashimoto et al., 2005; Idris et al., 2005; Jentsch et al., 1997) . Hypofrontality (frontal lobe dysfunction in schizophrenia) from PCP treatment is present 72 h after the withdrawal of subchronic PCP treatment (Cochran et al., 2003) . Hypofrontality correlates with the severity and presence of negative symptoms and cognitive deficits in schizophrenic patients (Andreasen et al., 1992; Buchsbaum et al., 1990; Schroder et al., 1994 Schroder et al., , 1996 Tamminga et al., 1992; Slifstein et al., 2015) . Xiao et al. (2011) reported that neuroactive ligands active at glutamate and GABA receptors are disrupted in the PFC of PCP-treated animals. Cochran et al. (2003) demonstrated that decreases in mRNA encoding the GABAergic interneuron calcium binding protein parvalbumin are also observed in the PFC in animals, in accordance with findings in post-mortem brain tissue of schizophrenic patients (Beasley and Reynolds, 1997; Danos et al., 1998) . In our experiments, DA and GABA levels after vehicle administration followed by object presentation to subchronic PCPtreated rats were lower than those in subchronic salinetreated rats (data not shown).
ASP5736 increased DA release in mPFC in subchronically PCP-treated rats in our microdialysis study, as predicted by immunohistochemical and electrophysiological studies (c.f. above). As D 1 receptor agonists are known to improve spatial working memory in aged monkeys (Cai and Arnsten, 1997; Goldman-Rakic et al., 2004) , the cognitive enhancing effect of this compound may well be related to similar effect. Moreover, PCP-induced cognitive deficits appear to be accompanied by, and possibly caused by, dysfunction of GABAergic inhibitory interneurons in the mPFC (Tanaka et al., 2011) . 5-HT 5A receptors are expressed on GABAergic neurons in the mPFC. ASP5736 increased GABA release in the mPFC, which might be induced by blocking the inhibitory 5-HT 5A receptors on these GABAergic neurons. This could be another mechanism of this compound to improve cognitive impairment induced by subchronic PCP treatment. These findings indicate that ASP5736 blocked inhibitory 5-HT 5A receptors on DAergic neurons in the VTA projecting to the mPFC ( Figure 4A ), and also on GABAergic interneurons in the mPFC ( Figure 4B ), thereby ASP5736 might improve cognitive impairment.
Taken together, based upon these findings, we hypothesize that the mode of action of ASP5736, which improves the cognitive deficits caused by PCP, might be related both to the activation of DAergic and GABAergic neurons in the mPFC through blockade of inhibitory 5-HT 5A receptors on DAergic neurons in the VTA projecting to the mPFC, and to the activation of GABAergic interneurons in the mPFC through blockade of inhibitory 5-HT 5A receptors on these neurons, respectively ( Figure 5 ). The preferential and significant stimulation of burst firing of midbrain dopamine neurons in the VTA by ASP5736, an effect which to our knowledge has not been hitherto observed, may represent a unique action of the drug with respect to its potential clinical utility in psychiatry, including schizophrenia.
